P415 MRI assessment of body composition in paediatric Crohn's disease; intra-abdominal adipose tissue association with disease severity

cell transplantation. Nine of these 13 patients were using concomitantly AZA and resting 4 patients have had AZA. Endoscopic remission was 70% (8 of 12) in the whole group. Conclusions: Nearly 25% of GIBD cases are refractory to immunmodulator and CS therapy. The major options in these cases are THD and anti-TNF blockers. With these medications remission can be obtained in approximately 75% of the cases. Stopping the medical treatment even in patients under remission, has no clear cut rules. However, one should remember that prominent vasculitic characteristic of the Behcet’s disease and GIBD may have a long term endoscopic remission without new flare.